Primary Bone Marrow Lymphoma: De Novo and Transformed Subtypes

References

• Wang G, Chang Y, Wu X, et al. Clinical features and prognostic factors of primary bone marrow lymphoma. Cancer Manag Res. 2019;11:2553–2563. doi:10.2147/CMAR.S187522
   PubMed Web of Science ®Google Scholar
• Yang CF, Hsiao LT, Chang HY, Hsu CY. Large B-cell lymphoma presenting primarily in bone marrow is frequently associated with haemophagocytic lymphohistiocytosis and has distinct cytogenetic features. Pathology. 2020;52(5):561–567. doi:10.1016/j.pathol.2020.04.005
   PubMed Web of Science ®Google Scholar
• Martinez A, Ponzoni M, Agostinelli C, et al. Primary bone marrow lymphoma: an uncommon extranodal presentation of aggressive non-Hodgkin lymphomas. Am J Surg Pathol. 2012;36(2):296–304. doi:10.1097/PAS.0b013e31823ea106
   PubMed Web of Science ®Google Scholar
• Wang HY, Yang CF, Chiou TJ, et al. Primary bone marrow lymphoma: a hematological emergency in adults with fever of unknown origin. Cancer Med. 2018;7(8):3713–3721. doi:10.1002/cam4.1669
   PubMed Web of Science ®Google Scholar
• Zamo A, Johnston P, Attygalle AD, Laurent C, Arber DA, Fend F. Aggressive B-cell lymphomas with a primary bone marrow presentation. Histopathology. 2020;77(3):369–379. doi:10.1111/his.14124
   PubMed Web of Science ®Google Scholar
• Chang H, Hung YS, Lin TL, et al. Primary bone marrow diffuse large B cell lymphoma: a case series and review. Ann Hematol. 2011;90(7):791–796. doi:10.1007/s00277-010-1129-4
   PubMed Web of Science ®Google Scholar
• Kazama H, Teramura M, Yoshinaga K, Masuda A, Motoji T. Long-term remission of primary bone marrow diffuse large B-cell lymphoma treated with high-dose chemotherapy rescued by in vivo rituximab-purged autologous stem cells. Case Rep Med. 2012;2012:957063. doi:10.1155/2012/957063
   PubMedGoogle Scholar
• Kim MS, Cho YU, Jang S, Seo EJ, Lee JH, Park CJ. A case of primary bone marrow diffuse large B-cell lymphoma presenting with fibrillar projections and hemophagocytic lymphohistiocytosis. Ann Lab Med. 2017;37(6):544–546. doi:10.3343/alm.2017.37.6.544
   PubMed Web of Science ®Google Scholar
• Messina C, Christie D, Zucca E, Gospodarowicz M, Ferreri AJ. Primary and secondary bone lymphomas. Cancer Treat Rev. 2015;41(3):235–246. doi:10.1016/j.ctrv.2015.02.001
   PubMed Web of Science ®Google Scholar
• Bhagavathi S, Fu K. Primary lymphoma of bone: a review. Semin Diagn Pathol. 2014;31(1):48–52. doi:10.1053/j.semdp.2014.01.004
   PubMed Web of Science ®Google Scholar
• Hong M, Wang S, Zhu H, Wang R, Li J, He G. Primary bone marrow lymphoma initially presenting with cytopenia: a report of eight cases. Blood. 2017;130(Supplement 1):5230. doi:10.1182/blood.V130.Suppl_1.5230.5230
   Google Scholar
• Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139(3):351–362. doi:10.1111/j.1365-2141.2007.06807.x
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022. doi:10.1182/blood.2022015851
   Web of Science ®Google Scholar
• Seegobin K, Li Z, Alhaj Moustafa M, et al. Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003–2018). Am J Hematol. 2022;97:1150–1158. doi:10.1002/ajh.26635
   PubMed Web of Science ®Google Scholar
• Cox MC, Di Napoli A, Scarpino S, et al. Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component. PLoS One. 2014;9(4):e93903. doi:10.1371/journal.pone.0093903
   PubMed Web of Science ®Google Scholar
• Kuhlman JJ, Moustafa MA, Jiang L, et al. Leukemic high grade B cell lymphoma is associated with MYC translocation, double hit/triple hit status, transformation, and CNS disease risk: the Mayo Clinic experience. Clin Lymphoma Myeloma Leuk. 2022;22(8):e815–e825. doi:10.1016/j.clml.2022.04.009
   PubMed Web of Science ®Google Scholar
• Zou D, Yi S, Cui R, et al. BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase. BMC Med Genet. 2017;18(1):16. doi:10.1186/s12881-017-0381-z
   PubMed Web of Science ®Google Scholar
• Muringampurath-John D, Jaye DL, Flowers CR, et al. Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. Br J Haematol. 2012;158(5):608–614. doi:10.1111/j.1365-2141.2012.09209.x
   PubMed Web of Science ®Google Scholar
• Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016;127(18):2182–2188. doi:10.1182/blood-2015-10-676700
   PubMed Web of Science ®Google Scholar
• Alvares CL, Matutes E, Scully MA, et al. Isolated bone marrow involvement in diffuse large B cell lymphoma: a report of three cases with review of morphological, immunophenotypic and cytogenetic findings. Leuk Lymphoma. 2004;45(4):769–775. doi:10.1080/10428190310001625746
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Chang JE, et al. NCCN guidelines (R) insights: B-cell lymphomas, version 5.2021. J Natl Compr Canc Netw. 2021;19(11):1218–1230. doi:10.6004/jnccn.2021.0054
   PubMed Web of Science ®Google Scholar
• Nishida H, Suzuki H, Hori M, Obara K. Primary isolated bone marrow diffuse large B cell lymphoma with long-term complete remission. Leuk Res Rep. 2018;10:11–15. doi:10.1016/j.lrr.2018.05.004
   PubMedGoogle Scholar
• Nabe Y, Kikuchi S, Kamihara Y, Wada A, Murakami J, Sato T. Early complete response of primary bone marrow B-cell lymphoma treated with rituximab-based CHOP therapy, assessed by flow cytometry and immunoglobulin heavy chain rearrangement. Clin Case Rep. 2021;9(8):e04657. doi:10.1002/ccr3.4657
   PubMed Web of Science ®Google Scholar
• Wang W, Zhou GY, Zhang W. Early relapse in a case of primary bone marrow diffuse large B-cell lymphoma treated with rituximab-CHOP. Immunotherapy. 2017;9(5):379–385. doi:10.2217/imt-2017-0005
   PubMed Web of Science ®Google Scholar
• Chen PT, Jorsan K, Avezbakiyev B, Akhtar C, Wang JC. Aggressive diffuse intermediate size B-cell lymphoma with P53 mutation presented as primary bone marrow lymphoma. J Investig Med High Impact Case Rep. 2020;8:2324709620982765. doi:10.1177/2324709620982765
   Web of Science ®Google Scholar
• Reed A, Sommerhalder D. The use of R-hyper-CVAD in a rare case of primary bone marrow diffuse large B-cell lymphoma. J Hematol. 2019;8(4):165–167. doi:10.14740/jh559
   PubMed Web of Science ®Google Scholar
• Evans MG, Rezk SA, Pinter-Brown LC, Zhao X. Aggressive CD5-positive primary bone marrow diffuse large B-cell lymphoma with leukemic presentation. Case Rep Hematol. 2021;2021:2628100. doi:10.1155/2021/2628100
   PubMed Web of Science ®Google Scholar